

**Amendments to the Specification:**

Please add the following line at page 6, after line 27:

Fig. 13 shows ceramide catabolic pathways.

Please replace the line on page 18, line 30 with the following:

5'-TATACAGAGCTCCGTAGGAC-3' (SEQ ID NO: 1)

Please replace the line on page 19, line 1 with the following:

5'-AGTTGTCTGCAGCCACGAAC-3' (SEQ ID NO: 2)

Please replace the line on page 30, line 1 with the following:

**Table IV** Primer Sequences and Number of Cycles of Amplification

Please replace the Table on page 30, beginning at line 3 with the following table:

Gene	Primer	Sequence (5'- 3')	Annealing temper.	No. of cycles	Product Size	SEQ ID NOs:
GAPDH	sense	AAT CCC ATC ACC ATC TTC CA	52	16	558	3
	antisense	GTC ATC ATA TTT GGC AGG TT				4
CD1d	sense	GCT CAA CCA GGA CAA GTG GAC GAG	66	27	452	5
	antisense	AGG AAC AGC AAG CAC GCC AGG ACT				6

Please replace the Table on page 30, beginning at line 6 with the following:

Gene	Primer	Sequence (5'- 3')	Annealing temper.	No. of cycles	Product Size	SEQ ID NOs:
GAPDH	sense	TTC ACC ACC ATG GAG AAG GC	60	22	236	7
	antisense	GGC ATG GAC TGT GGT CAT GA				8
CD1d.1	sense	ACG TCC TGG CAG ACA GTC CCA GG	60	24	706	9
	antisense	TTA ATG TTG AAA AGA GCG TAC TGG C				10

Please replace the line on page 35, line 1 with the following:

**Table V** The main family of lipids regulated by CD<sub>1d</sub> in skin were phospholipids

Please add the following, centered at page 36, line 20:

Fig. 13

Please replace the line on page 37, line 1 with the following:

**Table VI** For the large intestine the following results were obtained:

Please replace the line on page 38, line 1 with the following:

**Table VII** For the small intestine the following results were obtained::